Alpha Tau Medical Ltd. DRTS

Nasdaq · oncology · unclear · EDGAR · Updated Oct 24, 2026

Alpha Tau Medical Ltd. (Nasdaq: DRTS) is an oncology medical device company.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Program	Indication	Modality	Stage
Alpha DaRT - ReSTART pivotal trial	Recurrent cutaneous squamous cell carcinoma (US)	unclear	NA_NON_THERAPEUTIC
Alpha DaRT - Japan head and neck	Unresectable locally advanced or locally recurrent head and neck cancer	unclear	NA_NON_THERAPEUTIC
Alpha DaRT - Israel SCC	SCC of the skin or oral cavity	unclear	NA_NON_THERAPEUTIC
Alpha DaRT - REGAIN trial	Recurrent glioblastoma multiforme (US)	unclear	NA_NON_THERAPEUTIC

Oct 22, 2026
n/a Alpha Tau signed an MOU with Samsung Medical Center to explore a potential clinical trial of Alpha DaRT for pancreatic cancer patients in South Korea.Signing this MOU with Samsung Medical Center, one of the world's leading medical centers, is an important step forward in our goal to bring Alpha DaRT to cancer patients wherever they are. Filing
Oct 19, 2026
n/a FDA approved an IDE supplement expanding REGAIN from 10 to 20 patients, adding PFS and quality-of-life endpoints and an additional interim analysis (trial-design change, not a marketing decision).The U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplement expanding its U.S. REGAIN trial. Filing
Aug 10, 2026
positive Final data from Israeli pilot of Alpha DaRT plus pembrolizumab in HNSCC: 100% ORR in 9 evaluable patients (4 CR, 5 PR), median OS 18.2 months, median PFS 5.4 months; study stopped for success under its two-stage design.Among evaluable patients, treatment with Alpha DaRT plus pembrolizumab produced an objective response rate (i.e., systemic complete response plus partial response) of 100%, including four complete responses and five partial responses, for a complete response rate of 44%. Filing

5 more on record.

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export